Igenica, Inc. is a biopharmaceutical company pioneering breakthrough antibody-based cancer medicines. The company has integrated innovative technology platforms to address the major challenges to developing effective treatments for multiple oncology indications, with sTAg, a new approach to discovering and prioritizing novel tumor antigens, and iTAb, a functional in vivo antibody screening approach. Collectively, the two technology platforms drive Igenica's drug discovery efforts and promise to identify novel and more effective cancer therapeutics.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/12/12 | $33,000,000 | Series C |
5AM Ventures OrbiMed Advisors The Column Group Third Rock Ventures | undisclosed |
